Oxymetholone for the treatment of HIV-wasting: A double-blind, randomized, placebo-controlled phase III trial in eugonadal men and women

HIV Clinical Trials

Volumn 4, Issue 3, 2003, Pages 150-163

  Hengge, Ulrich R ^a   Stocks, Kristin ^e   Faulkner, Sandy ^b   Wiehler, Heidi ^c   Lorenz, Christine ^c   Jentzen, Walter ^c   Hengge, Dagmar ^d   Ringham, Gary ^b  

^a HEINRICH HEINE UNIVERSITY   (Germany)

^b Unimed Pharmaceuticals Inc   (United States)

^c UNIVERSITY OF DUISBURG ESSEN   (Germany)

^d UNIVERSITY OF BONN   (Germany)

^e NONE

Author keywords

Anabolic steroids; HIV; Liver; Oxymetholone; Quality of life; Testosterone; Wasting; Weight loss

Indexed keywords

ALANINE AMINOTRANSFERASE; ANABOLIC AGENT; ANTIRETROVIRUS AGENT; ASPARTATE AMINOTRANSFERASE; FOLLITROPIN; GAMMA GLUTAMYLTRANSFERASE; LUTEINIZING HORMONE; OXYMETHOLONE; PLACEBO; PROTEINASE INHIBITOR; TESTOSTERONE;

ABDOMINAL PAIN; ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; APPETITE; ARTICLE; ASTHENIA; BACKACHE; BACTERIAL INFECTION; BODY MASS; BODY WEIGHT; BRONCHITIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DIARRHEA; DISEASE ASSOCIATION; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRY SKIN; ENERGY METABOLISM; FEMALE; FOOD INTAKE; HAIR LOSS; HEADACHE; HEPATOMEGALY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HORMONAL REGULATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMPEDANCE; INFLUENZA; JAUNDICE; LEAN BODY WEIGHT; LEG CRAMP; LIVER DISEASE; MAJOR CLINICAL STUDY; MALE; MUSCLE WEAKNESS; MYALGIA; MYCOSIS; NAUSEA; NECK PAIN; PATIENT CARE; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SELF EXAMINATION; THORAX PAIN; TREATMENT OUTCOME; VIRUS INFECTION; WASTING SYNDROME; WEIGHT GAIN; WELLBEING;

ADULT; AGED; APPETITE; BODY COMPOSITION; BODY WEIGHT; DOUBLE-BLIND METHOD; FEMALE; HIV INFECTIONS; HIV WASTING SYNDROME; HORMONES; HUMANS; MALE; MIDDLE AGED; OXYMETHOLONE; QUALITY OF LIFE;

EID: 0038676894     PISSN: 15284336     EISSN: None     Source Type: Journal    
DOI: 10.1310/9V0C-YADY-UJNV-T2RT     Document Type: Article

References (56)

1. Teixeira A, Leu JC, Honderlick P, et al. Variation in body weight and plasma viral load in HIV patients treated with tritherapy including a protease inhibitor [abstract]. Nutrition. 1997;13:269.
2. Wanke CA, Silva M, Knox TA, Forrester J, Speigelman D, Gorbach SL. Weight loss and wasting remain common complications in individuals infected with human immunodeficiency virus in the era of highly active antiretroviral therapy. Clin Infect Dis. 2000;31:803-805.
3. Corcoran C, Grinspoon S. Treatments for wasting in patients with the acquired immunodeficiency syndrome. N Engl J Med. 1999;340:1740-1750.
4. Nemechek PM, Polsky B, Gottlieb MS. Treatment guidelines for HIV-associated wasting. Mayo Clin Proc. 2000;75:386-394.
5. Dobs AS, Dempsey MA, Ladenson PW, Polk BF. Endocrine disorders in men infected with the human immunodeficiency virus. Am J Med. 1988;84:611-616.
6. Coodley GO, Loveless MO, Nelson HD, Coodley MK. Endocrine function in the HIV wasting syndrome. J Acquir Immune Defic Syndr. 1994;7:46-51.
7. Kotler DP, Burastero S, Wang J, Pierson RN Jr. Prediction of body cell mass, fat-free mass, and total body water with bioelectrical impedance analysis: effects of race, sex, and disease. Am J Clin Nutr. 1996;64:489S-497S.
8. Silva M, Skolnik PR, Gorbach SL, et al. The effect of protease inhibitors on weight and body composition in HIV-infected patients. AIDS. 1998;12:1645-1651.
9. Schwenk A, Beisenherz A, Kremer G, Diehl V, Salzberger B, Fatkenheuer G. Bioelectrical impedance analysis in HIV-infected patients treated with triple antiretroviral treatment. Am J Clin Nutr. 1999;70:867-873.
10. Berger D, Cimoch P, Nemechek PM, et al. Measurement of body cell mass in patients receiving highly active antiretroviral therapy (HAART). In: Program and abstracts of the 37th annual meeting of the Interscience Conference on Antimicrobial Agents and Chemotherapy; September 28-October 1, 1997; Toronto, Ontario.
11. Zueman D, Teixeira A, Olivieri M, et al. Correlation between body composition, caloric intake and plasma viral load in HIV infected patients [abstract]. Nutrition. 1997;13:293.
12. Oster MH, Enders SR, Samuels SJ, et al. Megestrol acetate in patients with AIDS and cachexia. Ann Intern Med. 1994;121:400-408.
13. Von Roenn JH, Armstrong D, Kotler DP, et al. Megestrol acetate in patients with AIDS-related cachexia. Ann Intern Med. 1994;121:393-399.
14. Hoh R, Pelfini A, Neese RA, Chan M, et al. De novo lipogenesis predicts short-term body-composition response by bioelectrical impedance analysis to oral nutritional supplements in HIV-associated wasting. Am J Clin Nutr. 1998;68:154-163.
15. Schambelan M, Mulligan K, Grunfeld C, et al. Recombinant human growth hormone in patients with HIV-associated wasting. A randomized, placebo-controlled trial. Serostim Study Group. Ann Intern Med. 1996;125:873-882.
16. Grinspoon S, Corcoran C, Askari H, et al. Effects of androgen administration in men with the AIDS wasting syndrome. A randomized, double-blind, placebo-controlled trial. Ann Intern Med. 1998;129:18-26.
17. Strawford A, Barbieri T, Van Loan M, et al. Resistance exercise and supraphysiologic androgen therapy in eugonadal men with HIV-related weight loss: a randomized controlled trial. JAMA. 1999;281:1282-1290.
18. Forbes GB. The effect of anabolic steroids on lean body mass: the dose response curve. Metabolism. 1985;34:571-573.
19. Forbes GB, Porta CR, Herr BE, Griggs R. Sequence of changes in body composition induced by testosterone and reversal of changes after drug is stopped. JAMA. 1992;267:397-399.
20. Arnold A, Potts GO, Beyler AL. Evaluation of the protein anabolic properties of certain orally active anabolic agents based on nitrogen balance studies in rats. Endocrinology. 1963;72:408-417.
21. Camerino B, Sala G. Anabolic steroids. Prog Drug Res. 1960;2:71-134.
22. Pavlatos AM, Fultz O, Monberg MJ, Vootkur A. Review of oxymetholone: a 17alpha-alkylated anabolic-androgenic steroid. Clin Ther. 2001;23:789-801.
23. Hengge UR, Baumann M, Malessa R, Brockmeyer NH, Goos M. Oxymetholone promotes weight gain in patients with advanced human immunodeficiency virus (HIV-1) infection. Br J Nutr. 1996;75:129-138.
24. Hengge UR, Brockmeyer NH, Goos M. Megestrol for AIDS-related anorexia. Ann Intern Med. 1995;122:879.
25. Kramer HJ, Ulmer HV. Reference values for body fat content as a measure for desirable body fat content. Z Ernahrungswiss. 1984;23:1-11.
26. Ott M, Lembcke B, Fischer H, et al. Early changes of body composition in human immunodeficiency virus-infected patients: tetrapolar body impedance analysis indicates significant malnutrition. Am J Clin Nutr. 1993;57:15-19.
27. Van Loan MD, Strawford A, Jacob M, Hellerstein M. Monitoring changes in fat-free mass in HIV-positive men with hypotestosteronemia and AIDS wasting syndrome treated with gonadal hormone replacement therapy. AIDS. 1999;13:241-248.
28. Corcoran C, Anderson EJ, Burrows B, et al. Comparison of total body potassium with other techniques for measuring lean body mass in men and women with AIDS wasting. Am J Clin Nutr. 2000;72:1053-1058.
29. Wu AW, Rubin HR, Mathews WC, et al. A health status questionnaire using 30 items from the Medical Outcomes Study. Preliminary validation in persons with early HIV infection. Med Care. 1991;29:786-798.
30. Macallan DC, Noble C, Baldwin C, Foskett M, McManus T, Griffin GE. Prospective analysis of patterns of weight change in stage IV human immunodeficiency virus infection. Am J Clin Nutr. 1993;58:417-424.
31. Kotler DP, Tierney AR, Wang J, Pierson RN Jr. Magnitude of body-cell-mass depletion and the timing of death from wasting in AIDS. Am J Clin Nutr. 1989;50:444-447.
32. Severson K, Nemechek P. Free testosterone as a predictor for body composition changes in males with HIV or AIDS [abstract]. In: Program and abstracts of the XI International Conference on AIDS; July 7-12, 1996; Vancouver, British Columbia. Abstract:Tu.B. 2385.
33. Berger D, Muurshainen N, Witten B, et al. Hypogonadism and wasting in the era of HAART in HIV-infected patients [abstract]. In: Program and abstracts of the XII World AIDS Conference; June 28 to July 3, 1998; Geneva, Switzerland. Abstract 32174.
34. Wagner GJ, Rabkin JG. Testosterone therapy for clinical symptoms of hypogonadism in eugonadal men with AIDS. Int J STD AIDS. 1998;9:41-44.
35. Grinspoon S, Corcoran C, Miller K, et al. Body composition and endocrine function in women with acquired immunodeficiency syndrome wasting. J Clin Endocrinol Metab. 1997;82:1332-1337. [Erratum, J Clin Endocrinol Metab. 1997;82:3360).
36. Shibuya A, Ninomiya N, Nakazawa M, Nagasawa T, Yoda Y, Abe T. Oxymetholone therapy with familial antithrombin III deficiency. Thromb Haemost. 1988;60:495-497.
37. Loprinzi CL. Effect of megestrol acetate on the human pituitary-adrenal axis. Mayo Clin Proc. 1992;67:1160-1162.
38. Kaplan G, Thomas S, Fierer DS, et al. Thalidomide for the treatment of AIDS-associated wasting. AIDS Res Hum Retroviruses. 2000;16:1345-1355.
39. Clark RH, Feleke G, Din M, et al. Nutritional treatment for acquired immunodeficiency virus-associated wasting using beta-hydroxy beta-methylbutyrate, glutamine, and arginine: a randomized, double-blind, placebo-controlled study. J Parenter Enteral Nutr. 2000;24:133-139.
40. Shabert JK, Winslow C, Lacey JM, Wilmore DW. Glutamine-antioxidant supplementation increases body cell mass in AIDS patients with weight loss: a randomized, double-blind controlled trial. Nutrition. 1999;15:860-864.
41. Grinspoon S, Corcoran C, Anderson E, et al. Sustained anabolic effects of long-term androgen administration in men with AIDS wasting. Clin Infect Dis. 1999;28:634-636.
42. Strawford A, Barbieri T, Neese R, et al. Effects of nandrolone decanoate therapy in borderline hypogonadal men with HIV-associated weight loss. J Acquir Immune Defic Syndr Hum Retrovirol. 1999;20:137-146.
43. Miller K, Corcoran C, Armstrong C, et al. Transdermal testosterone administration in women with acquired immunodeficiency syndrome wasting: a pilot study. J Clin Endocrinol Metab. 1998;83:2717-2725.
44. Berger JR, Pall L, Hall CD, Simpson DM, Berry PS, Dudley R. Oxandrolone in AIDS-wasting myopathy. AIDS. 1996;10:1657-1662.
45. Gold J, High HA, Li Y, et al. Safety and efficacy of nandrolone decanoate for treatment of wasting in patients with HIV infection. AIDS. 1996;10:745-752.
46. Homeyn M, Gunn N III. Resistance exercise and oxandrolone for men with HIV-related weight loss. JAMA. 2000;284:176.
47. Grinspoon S, Corcoran C, Parlman K, et al. Effects of testosterone and progressive resistance training in eugonadal men with AIDS wasting. A randomized, controlled trial. Ann Intern Med. 2000;133:348-355.
48. Grinspoon S, Corcoran C, Lee K, et al. Loss of lean body and muscle mass correlates with androgen levels in hypogonadal men with acquired immunodeficiency syndrome and wasting. J Clin Endocrinol Metab. 1996;81:4051-4058.
49. Helle SI, Ueland T, Ekse D, et al. The insulin-like growth factor system in human immunodeficiency virus infection: relations to immunological parameters, disease progression, and antiretroviral therapy. J Clin Endocrinol Metab. 2001;86:227-233.
50. Lo JC, Mulligan K, Noor MA, et al. The effects of recombinant human growth hormone on body composition and glucose metabolism in HIV-infected patients with fat accumulation. J Clin Endocrinol Metab. 2001;86:3480-3487.
51. Zimmerman HJ. Drug-induced liver disease. Drugs. 1978;16:25-45.
52. Turani H, Levi J, Zevin D, Kessler E. Hepatic lesions in patients on anabolic androgenic therapy. Israel J Med Sci. 1983;19:332-337.
53. Williams G, Ghatei M, Burrin J, Bloom S. Severe hyperglucagonemia during treatment with oxymetholone. Br Med J. 1986;292:1637-1638.
54. Wilson IB, Roubenoff R, Knox TA, Spiegelman D, Gorbach SL. Relation of lean body mass to health-related quality of life in persons with HIV. J Acquir Immune Defic Syndr. 2000;24:137-146.
55. Kong A, Edmonds P. Testosterone therapy in HIV wasting syndrome: systematic review and meta-analysis. Lancet Infect Dis. 2002;2(11):692-699.
56. Hengge U. HIV and testosterone therapy. Lancet Infect Dis. 2003;3(4):187-188.